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An increasing death rate due to cardiovascular disease in patients with rheumatoid arthritis (RA) has
been reported. Keishibukuryogan (KBG) is a traditional Chinese/Japanese (Kampo) formula that has
been administered to patients with blood stagnation, e.g. thrombotic disease and atherosclerosis. The
objective of this study was to evaluate the efficacy of KBG on disease activity and endothelial
dysfunction in RA patients. Sixteen RA patients were enrolled and administered KBG (12 g per day) for
12 weeks in addition to continuing other drugs. The disease activity of RA was assessed by modified
disease activity scores for 28 joints (DAS28). Plasma levels of adhesion molecules, soluble E-selectin
(sE-selectin), soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular cell adhesion
molecule-1 (sVCAM-1) were evaluated. C-reactive protein (CRP), inflammatory cytokines (IL-1b, IL-6
and TNF-a) and lipid peroxide (LPO) were also evaluated. Fourteen patients completed the study. The
disease activity of RA, tender joint count, swollen joint count and DAS28 decreased significantly.
Among adhesion molecules, only sVCAM-1 decreased significantly. LPO also decreased significantly,
whereas CRP and inflammatory cytokines remained unchanged. These results suggest that KBG has
insufficient anti-inflammatory or immunomodulating effect but does have a beneficial effect on articular
symptoms and a protective effect against endothelial dysfunction in RA patients.
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Introduction
Rheumatoid arthritis (RA) is a chronic articular inflammatory
disease and leads to tenderness, swelling and destruction of
systemic joints. Shortening of life span and increasing death
rate due to cardiovascular and cerebrovascular diseases in RA
patients have been reported (1,2). The high incidence of
cardiovascular events in RA patients cannot be entirely
explained by only traditional cardiac risk factors (3), and
increased levels of adhesion molecules are associated with
inflammatory activity in RA patients (4).
In the early phase of atherosclerosis, leucocytes migrate
trans-endothelially into the vascular wall (5). This process is
mediated by adhesion molecules, which are expressed on the
vascular endothelium, and circulating leukocytes in response
to several inflammatory stimuli (6,7). Selectins and their
ligands are involved in the rolling and tethering of leukocytes
on the vascular wall. Intercellular adhesion molecules
(ICAMs) and vascular cell adhesion molecule-1 (VCAM-1),
as well as some integrins, induce firm adhesion of inflammat-
ory cells to the vascular surface (8–10). In most of the cell
adhesion molecules, soluble forms have been identified in the
circulation. Several lines of evidence have supported a crucial
role of cell adhesion molecules in the development of
atherosclerotic plaque, and plasma levels of soluble E-selectin
(sE-selectin), soluble ICAM (sICAM-1) and soluble VCAM-1
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Cell adhesion molecules also play an important role in the
process of destruction of synovial tissue in RA patients. The
activation, circulation and migration of mononuclear cells to
inflammatory sites are regulated by cell adhesion molecules
(11,12). In fact, the plasma levels of sE-selectin, sICAM-1 and
sVCAM-1 reflect the activity of RA (13,14). Together with the
fact of the increasing death rate due to cardiovascular diseases
in RA patients, cell adhesion molecules might be associated
not only with the pathological progression of synovial tissue
but also with the atherosclerotic progression of vascular tissue
in RA patients.
Currently, Western medicine is commonly used, but
traditional Chinese/Japanese (Kampo) medicine also has a
long history of contributing to medical care in Japan (15). In
essence, Kampo formulas are prescribed according to the
characteristic pathological concept of Kampo medicine (16).
Keishibukuryogan (KBG) (Gui-Zhi-Fu-Ling-Wan in Chinese)
is a Kampo formula composed of five kinds of medicinal
plants, Cinnamomum cassia Blume (Cinnamomi cortex),
Paeonia lactiflora Pallas (Paeoniae radix), Paeonia suffru-
ticosa Andrews (Moutan cortex), Prunus persica Batsch
(Persicae semen) and Poria cocos Wolf (Hoelen) (Table 1).
In Japan, KBG has been administered to patients with blood
stagnation, e.g. thrombotic disease and atherosclerosis. The
contemporary practice of Kampo medicine is required to be
evidence based (17). We have previously reported that KBG
improves microcirculation in patients with multiple old
lacunar infarction (18) and that it prevents the progression of
atherosclerosis and preserves endothelium-dependent vasore-
laxation in cholesterol-fed rabbit by its antioxidant activity
(19,20). Therefore, it is expected that KBG might prevent the
progression of vascular endothelial activation in RA patients.
We conducted this clinical study for the purpose of evaluating
the effects of KBG on endothelial dysfunction and disease
activity in RA patients.
Methods
Patients
The patients enrolled in the study were diagnosed as suffering
from RA according to the 1987 diagnostic criteria for RA of
the American Rheumatism Association (21) and the revised
criteria of the American College of Rheumatology (22).
Diagnoses were made at the Department of Japanese Oriental
Medicine, Toyama University Hospital, between September
2002 and January 2004. At this point, patients had been
receiving constant treatment with non-steroidal anti-
inflammatory drugs (NSAIDs), disease-modifying anti-
rheumatic drugs (DMARDs), corticosteroid (prednisolone
< 5mg per day) or other drugs for at least 3 months and had
been in a stable condition in terms of the disease activity of
RA. Smokers were excluded from entry. No patients had
clinical or laboratory signs of liver or kidney disease,infection,
diabetes mellitus, malignancy, previous stroke or myocardial
infarction.
Drug
KBG consists of five dried herbal medicines: Cinnamomi
cortex, Peoniae radix, Moutan cortex, Persicae semen and
Hoelen. These herbal powders were mixed with boiled honey
in the ratio shown in Table 1 and rolled up into balls (2 g each).
All these herbal medicines and honey were purchased from
Uchida Wakanyaku (Tokyo, Japan).
Study Design
The recruited RA patients were administered KBG (12 g per
day) after meals three times a day for 12 weeks in addition to
their prescribed drugs. During the study, other medications
could not be newly introduced. Clinical and laboratory
assessments were performed at week 0 and week 12. The
study design was approved by the Human Subjects Committee,
University of Toyama. All patients provided written informed
consent in accordance with the ethical guidelines set forth in
the 1975 Declaration of Helsinki.
Assessment of RA Activity
For the assessment of the disease activity of RA, disease
activity scores for 28 joints (DAS28) (23) were evaluated by
rheumatologists. In detail, tender joint count (0–28) (T28),
swollen joint count (0–28) (S28), erythrocyte sedimentation
rate (ESR) and the patients’ global assessment of disease
activity [general health (GH)] using a visual analog scale
(VAS; 0–100 mm) were evaluated. Then, DAS28 was
calculated using the following equation:
DAS28 ¼ 0:56 ·
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
T28 ½ 
p
þ 0:28 ·
ﬃﬃﬃﬃﬃﬃﬃﬃﬃ
S28 ½ 
p
þ 0:70 · In ESR ½  þ 0:014 · GH ½ 
Clinical Laboratory Assessment
Blood was collected after overnight fasting, and separated
plasma was frozen at  80 C immediately and stored until
assay. As markers of endothelial dysfunction, levels of
sE-selectin, sICAM-1 and sVCAM-1 were measured by
enzyme-linked immunosorbent assay (ELISA) at a commer-
cial laboratory (SRL, Tokyo, Japan). Inflammatory cytokines,
Table 1. Herbal medicines composing KBG and their ratio
Herbal medicine Ratio (g)
Cinnamomi cortex Cinnamomum cassia Blume Gui-Zhi 0.2
Paeoniae radix Paeonia lactiflora Pallas Shao-Yao 0.2
Moutan cortex Paeonia suffruticosa Andrews Mu-Dan-Pi 0.2
Persicae semen Prunus persica Batsch Tao-Ren 0.2
Hoelen Poria cocos Wolf Fu-Ling 0.2
These five herbal powders were mixed with boiled honey (1 g) and rolled up
into balls (2 g each).
360 Effect of keishibukuryogan on rheumatoid arthritisinterleukin-1b (IL-1b; R&D Systems Inc., Minneapolis, MN),
interleukin-6 (IL-6; Endogen Inc., Woburn, MA) and tumor
necrosis factor-a (TNF-a; Endogen Inc.) were measured by
ELISA kit according to the manufacturer’s instructions. As a
marker of oxidative stress, lipid peroxide (LPO) was measured
by lipid peroxidation assay kit (Determina LPO; Kyowa
Medics, Tokyo, Japan). C-reactive protein (CRP), total
cholesterol (T-chol), high-density lipoprotein cholesterol
(HDL-chol), low-density lipoprotein cholesterol (LDL-chol)
and triglyceride were measured using standard laboratory
techniques in our hospital.
Statistical Analysis
Statistical analysis was performed with Stat View J-4.5
(Abacus Concept, Berkley, CA). Data were expressed as
mean ± SE. The difference between week 0 and week 12 was
analyzed using the Wilcoxon signed-rank test. A value of
P < 0.05 was considered statistically significant.
Results
Patient Characteristics
Sixteen patients were initially enrolled in this study. Two
patients dropped out because of acute bronchitis and bad
compliance with treatment. Finally, 14 patients completed the
study with no adverse events. The characteristics of the
patients analyzed are shown in Table 2.
Activity of RA
Disease activity of RA is shown in Table 3. T28 (P < 0.05), S28
(P < 0.05) and DAS28 (P < 0.05) were significantly decreased
at week 12 by administration of KBG compared with baseline,
but GH and ESR were not changed.
Clinical Laboratory Parameters
For the plasma levels of adhesion molecules, markers of
endothelial activation, sE-selectin (77.8 ± 9.2 versus 74.1 ±
9.6 ng ml
 1) and sICAM-1 (291.7 ± 32.0 versus 295.0 ±
31.5 ng ml
 1) were unchanged, but sVCAM-1 was decreased
significantly by 12 week KBG administration (857.1 ± 51.5
versus 744.6 ± 47.3 ng ml
 1; P < 0.01) (Fig. 1). The plasma
level of LPO, a marker of oxidative stress, also significantly
decreased at week 12 compared with baseline (P < 0.05),
whereas the values of the inflammatory marker CRP and the
inflammatory cytokines IL-1b, IL-6 and TNF-a were
unaltered (Table 4). T-chol, HDL-chol, LDL-chol and trigly-
ceride also remained unchanged (data not shown).
Discussion
In the present study, the administration of KBG for 12 weeks
did not reduce inflammatory markers or inflammatory
cytokines in RA patients. From this, it is suggested that KBG
does not possess sufficient anti-inflammatory or immuno-
modulating effect. In essence, we think that Kampo medicines
should be used for RA patients in combination with common
Western medicines, particularly when the RA disease activity
is high. In this study, constant treatment regimens using
Table 3. Disease activity of RA evaluated by disease activity score for 28
joints at baseline and after 12 weeks of KBG treatment
Week 0 Week 12 P-value
T28 (0–28) 3.6 ± 1.7 0.9 ± 0.3 <0.05
S28 (0–28) 2.5 ± 0.8 1.2 ± 0.4 <0.05
GH (VAS; 0–100 mm) 46.0 ± 5.6 41.3 ± 5.5 NS
ESR (mm h
 1) 67.9 ± 9.9 71.1 ± 8.1 NS
DAS28 4.7 ± 0.3 4.1 ± 0.3 <0.05
Data representmean ± SE(n ¼ 14). T28, tender joint count(0–28); S28, swollen
joint count (0–28); GH, patient’s global assessment of disease activity (general
health); VAS, visual analog scale; ESR, erythrocyte sedimentation rate;
DAS28, disease activity score for 28 joints; NS, not significant.
Table 2. Patient characteristics
Age (years) 59.1 ± 2.7
Duration of RA (years) 12.1 ± 1.7
Sex (male/female) 0/14
BMI (kg m
 2) 21.8 ± 0.7
Anatomical stage of RA
Stage I 0
Stage II 3
Stage III 2
Stage IV 9
Functional class of RA
Class I 5
Class II 6
Class III 3
Class IV 0
Complication
Hypertension 6
Hyperlipidemia 2
Concomitant drugs
NSAIDs 9
Corticosteroid 3
DMARDs
Bucillamine 5
Salazosulfapyridine 4
Methotrexate 3
Antihypertensive 2
HMG-CoA reductase inhibitor 1
Kampo medicines except KGB 13
Data represent mean ± SE (n ¼ 14) or number of cases. RA, rheumatoid
arthritis; BMI, body mass index; NSAIDs, non-steroidal anti-inflammatory
drugs; DMARDs, disease-modifying anti-rheumatic drugs; HMG-CoA,
2-hydroxyl-3-methylglutaryl coenzyme A; KBG, keishibukuryogan.
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for at least 3 months before the KBG administration, and only
patients who had been in a stable condition in terms of disease
activity of RA during this period were enrolled. In fact, the
ESR and CRP levels of our patients at 3 months prior to, and
right before, KBG administration were not significantly
different (ESR, 63.8 ± 9.5 versus 67.9 ± 9.9 mm h
 1; CRP,
1.90 ± 0.51 versus 1.82 ± 0.51 mg dl
 1). Common Western
medicines might already have modulated the plasma levels of
inflammatory cytokines prior to KBG administration. Indeed,
the plasma inflammatory cytokine levels in our patients were
relatively low compared with those of RA patients in another
report (24). We cannot rule out the possibility that KBG, when
used alone in RA patients, will reduce inflammatory cytokine
levels.
In our study, KBG decreased tender joint count, swollen
joint count and disease activity of RA as evaluated by DAS28,
and also a marker of oxidative stress, the plasma level of LPO.
RA patients are exposed to oxidative stress (25,26), and it was
reported that antioxidants decrease pain parameters, improve
RA activity and decrease oxidative stress markers (27,28).
KGB consists of the phenol-containing herbal medicines
Cinnamomi cortex, Paeoniae radix and Moutan cortex, and it
has antioxidant activity (19,20). We speculate that the
antioxidant effect of KBG might have contributed to the
reduction in articular symptoms of the RA patients observed in
this study.
Traditionally, KBG has been used for improvement of not
only blood stagnation but also dysmenorrhea. For this reason,
KBG is more likely to be administered to females than males.
Further, the morbidity rate of RA in females is higher than in
males. By coincidence, and the reason that smokers were
excluded from entry, all of the patients in this study were
females. Thus, we cannot rule out the possibility that male RA
patients might exhibit a different response to KBG than female
RA patients.
In this study, KBG did not decrease the plasma levels of
sE-selectin and sICAM-1, but it reduced sVCAM-1, one of the
markers of vascular endothelial activation. The plasma level of
sVCAM-1 is higher in RA patients than in osteoarthritis
patients (13) and decreases by a reduction in disease activity
(13,14). VCAM-1 is expressed on impaired endothelium and is
regulated by various factors such as inflammatory cytokines
(29). In this study, KBG did not change the plasma cytokine
levels in RA patients, suggesting that KBG downregulates
sVCAM-1 through a certain pathway not involving cytokines.
It is reported that vitamin E, an antioxidant, downregulates
sVCAM-1 in patients with hyperlipidemia (30). Therefore, we
speculate that the antioxidant effect of KBG might contribute
to the downregulation of VCAM-1.
It was reported that among adhesion molecules, VCAM-1
plays a major role in the progression of atherosclerosis (31),
can be a useful marker reflecting vascular endothelial
activation (24,30,32,33) and is associated with future cardio-
vascular events (34). We reported that KBG inhibits the
progression of atherosclerosis in cholesterol-fed rabbit (19)
and improves endothelial function in cholesterol-fed rabbit and
spontaneously hypertensive and diabetic rat (20,35,36), and
that Cinnamomi cortex and Paeoniae radix, medicinal herbs
used in KBG, have a vascular endothelial relaxation effect
through nitric oxide production (37,38). These effects of KBG
also suggest the benefit of this drug for vascular endothelial
function. There is another aspect concerning VCAM-1, as it
plays an important role as angiogenic mediator in the
Figure 1. Plasma levels of sE-selectin (A), sICAM-1 (B), and sVCAM-1 (C) at baseline and 12 weeks after administration of KBG. Data represent mean ± SE
(n ¼ 14), *P < 0.01 compared with baseline.
Table 4. Plasma levels of LPO, CRP and inflammatory cytokines at
baseline and after 12 weeks of KBG treatment
Week 0 Week 12 P-value
LPO (nmol ml
 1) 2.95 ± 0.67 1.46 ± 0.25 <0.05
CRP (mg dl
 1) 1.82 ± 0.51 2.14 ± 0.58 NS
IL-1b (pg ml
 1) 0.59 ± 0.09 0.54 ± 0.06 NS
IL-6 (pg ml
 1) 3.40 ± 0.95 2.37 ± 0.58 NS
TNF-a (pg ml
 1) 1.07 ± 0.48 1.10 ± 0.71 NS
Data represent mean ± SE (n ¼ 14). LPO, lipid peroxide; CRP, C-reactive
protein; IL-1b, interleukin-1b; IL-6, interleukin-6; TNF-a, tumor necrosis
factor-a; NS, not significant.
362 Effect of keishibukuryogan on rheumatoid arthritispathogenesis of RA by recruiting leukocytes to synovial tissue,
leading to proliferative synovitis (39,40). We speculate that the
reduction of sVCAM-1 might be one of the reasons for the
improving arthritic scores in this study.
The results obtained in the present study suggest that KBG
does not possess particular anti-inflammatory or immun-
omodulating effects but that it has a beneficial effect on
articular symptoms and a protective effect against endothelial
activation through the reduction of VCAM-1, and it may
thereby contribute to the prevention of the progression of
cardiovascular disorders in RA patients. Our hypothetical
representation of the effects of KBG on RA is summarized in
Fig. 2. This was a pilot study, and only patients with stable RA
activity achieved by common Western medicines were
enrolled, so the number of patients was limited. Further
studies based on randomized controlled trials or comparative
studies will be needed to validate the benefit of KBG in RA
patients.
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